Financing

[Market In] A Rosy Outlook After Two Years… CJ CGV’s Credit Outlook Downgraded as Expected

NICE Ratings and Hanwha Ratings Downgrade Outlook for Unsecured Bonds and Hybrid Capital Securities from “Positive” to “Stable” on the 30th Ratings Maintained at A- and BBB+, Respectively, but Outlook Remains Unchanged for the First Time in Two Years Market Concerns Raised at the Time of Olive Networks’ Acquisition Have Ultimately Come True Domestic Movie Attendance at Half 2019 Levels… “Delays in Earnings Recovery and Debt Reduction”

[Edaily Marketin Reporter LEE GEON-EOM ] NICEHoldings and Korea Credit Rating announced on the 30th that they have maintained the credit ratings of CJ CGV(079160)’s unsecured bonds at ‘A-’ and its hybrid capital securities at ‘BBB+’, respectively, while simultaneously downgrading the outlook from ‘Positive’ to ‘Stable’. The downgrade of the rating outlook is attributed to the delay in reducing the actual debt burden through the company’s own cash generation, as visible improvements in performance in the movie theater sector have been delayed.
(Photo: News1)


The market views this downgrade of the credit rating outlook as an “expected development.” Previously, credit rating agencies had raised CJ CGV’s rating outlook to “Positive” in 2024, reflecting the impact of CJ Olive Networks’ consolidation into the group’s financial statements and the possibility of support from group affiliates.

Even at that time, there were quite a few voices in some quarters of the market cautioning against overly optimistic forecasts. Critics pointed out that it was somewhat premature to raise the rating outlook based solely on the effects of the subsidiary’s consolidation, given that CJ CGV’s fundamental financial health—including its key financial indicators—had not yet fully recovered and remained at a non-investment-grade level. Consequently, as concerns raised at the time—such as the delayed recovery of demand in its core business, downside risks to earnings, and the burden of debt accumulated during the pandemic—have materialized, the rating outlook has returned to its original level after two years.

In fact, CJ CGV’s domestic theater business continues to struggle to restore its core profitability. Last year, the number of domestic movie theater attendees fell to 106.09 million, a 13.8% decrease from the previous year. This figure is less than half of the level seen in 2019, before the pandemic. Despite an increase in attendance during the first quarter of this year driven by the success of certain highly anticipated films, the company posted an operating loss of 6.6 billion won on a standalone basis.

Kwon Jin-hyuk, a senior researcher at Naisinpyeong, stated, “Although the company has continued efforts to restructure its revenue model—such as reducing fixed costs—since the pandemic, it is facing limitations in achieving tangible improvements in profitability due to a structural decline in audience demand and a lack of blockbuster hits.” He added, “As the recovery of the industry as a whole has stalled, it will be structurally difficult to return to pre-pandemic performance levels for the time being.”

Despite strong performance in IT services and overseas subsidiaries, the company’s overall financial burden remains excessive. Although CJ Olive Networks—which was acquired in June 2024—and overseas operations are performing well, the actual debt burden shows little sign of easing due to high financing costs, the burden of distributions on hybrid capital securities, and the accumulation of net losses, all against a backdrop of weakened operating cash flow generation.

Chae Seon-young, a senior analyst at Hanshin Rating, stated, “While the IT services and overseas theater segments are generating solid profits, the slump in the domestic theater business is offsetting these gains and limiting the company’s ability to service its debt using internally generated cash flow.” “In particular, when comprehensively considering factors such as the scale of hybrid securities—including hybrid capital securities—and the likelihood of fulfilling the capital replenishment commitments made to CGI Holdings’ financial investors (FIs), the actual financial burden is far heavier than what the accounting indicators suggest,” she analyzed.

However, comprehensive support from its parent company, CJ Corp., serves as a key pillar underpinning its creditworthiness. CJ Corp. has continued to bolster capital through large-scale rights offerings and hybrid capital loans in the past, as well as by providing capital replenishment commitments for the hybrid capital securities issued in April and May of this year, each worth 3000억원. Reflecting CJ Corp.’s strong capacity and willingness to provide support, both agencies have assigned CJ CGV a rating that is one notch higher than its standalone credit rating.

Meanwhile, the 35th and 40th bond-type hybrid capital securities were assigned a “BBB+” rating—one notch lower than the senior unsecured bonds (A-)—reflecting their long maturity (30 years), their capital-like characteristics (which allow for maturity extensions and interest payment deferrals under the same conditions), and the explicit inclusion of subordinated clauses.

In this regard, a CJ CGV official stated, “It was time to review an adjustment to the rating outlook, as two years have passed since we were assigned a stable outlook. Although the outlook was adjusted to ‘stable’ this time due to factors such as the delayed recovery of the domestic film market in 2025, we will strive to achieve another credit rating upgrade this year through a clear market recovery and the stabilization of our financial structure.”

Economy

Corporation

IT·Science

Economy

A Semiconductor Fabless Company Founded by SK Hynix’s Youngest-Ever Executive [VC Cradle]

The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
2026-07-04 09:00:07

Corporation

Genosco, Tax Risk?… “Lecraza Is ‘Royalty Income’; Its Value Remains Unchanged”

Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
2026-07-04 08:31:02

IT·Science

Celltrion Pharm Inc. Builds a Plant, AriBio Secures Investment… K-Bio in ‘Expansion Mode’ [Weekly Bio Roundup]

As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
2026-07-04 09:01:02